Sino Partners provides complete market entry advisory for Chinese biomedical technology, pharmaceutical, digital health and medical device businesses entering Australia and New Zealand - from TGA regulatory strategy and commercial positioning through to distribution, reimbursement and ongoing compliance.
China has emerged as a global leader in biomedical technology, genomics, digital health platforms and pharmaceutical manufacturing. A new generation of Chinese life sciences companies is producing genuinely innovative products that are competitive on quality, capability and price with established Western alternatives.
Australia and New Zealand's health systems represent high-value target markets for Chinese life sciences businesses - offering strong reimbursement frameworks, sophisticated clinical networks and a regulatory pathway (TGA/Medsafe) that, once navigated, provides credibility for broader Western market entry.
End-to-end market entry advisory for Chinese life sciences businesses entering Australia and New Zealand.
Australia's TGA is one of the world's most respected medical device regulators. TGA inclusion database registration or ARTG listing provides both market access and significant commercial credibility for Chinese medical device and diagnostic manufacturers.
Bringing Chinese pharmaceutical and biologic products to the Australian market requires both TGA registration and - for maximum commercial impact - PBS reimbursement listing. These are complex, multi-year processes that require careful strategic planning from the outset.
Australia's digital health market is one of the most active in the Asia-Pacific region, with significant government investment through the Australian Digital Health Agency and state health departments. Chinese digital health platform businesses need both regulatory compliance and deep understanding of government procurement processes to succeed.
Chinese MedTech and AgeTech businesses face a rapidly growing market in Australia as the population ages and technology adoption in health and care settings accelerates. Sino Partners provides complete commercialisation strategy from regulatory approval through to distribution network establishment and sales enablement.
Map your product to the correct TGA/Medsafe pathway and develop a clear timeline and evidence strategy.
Develop commercial strategy, channel strategy and pricing architecture for the Australian and New Zealand market.
Execute the regulatory submission process and manage approval through to market clearance.
Execute go-to-market strategy, establish distribution, and deliver first commercial results in the Oceania market.
Deep working knowledge of Australian and New Zealand therapeutic goods regulatory frameworks - the foundation of every successful healthcare market entry.
Understanding of NMPA processes, Chinese clinical evidence standards and how to leverage Chinese approval in TGA/Medsafe submissions.
We connect regulatory strategy to commercial strategy - ensuring your market entry investment translates into commercial returns.
Current intelligence on MBS, PBS and NDIS reimbursement frameworks - critical for pricing and commercial model design.
Established relationships with Australian clinical opinion leaders, health system procurement teams and specialist distributors.
From initial pathway assessment through to commercial launch and post-market compliance - one engaged team for the whole journey.
Contact our healthcare market entry team to map your regulatory pathway and commercial strategy.
Start a Conversation →